China on Wednesday confirmed that it slapped 10 Japanese auto parts manufacturers with a record $200 million (Rmb1.24bn) combined fine after the manufacturers were found guilty of price fixing.
According to a statement by the National Development & Reform Commission (NDRC), Sumitomo Electric, Jtekt, Denso, Asian Industry, NSK, Mitsubishi, Mitsuba, Furukawa, and NTN Corp were found guilty of involving in the illegal practice of price fixing.
The biggest individual fine, of Rmb290.4 million, was slapped on Sumitomo Electric. The amount of fine is equivalent to 6 per cent of the company's annual China revenues.
Two other Japanese manufacturers, viz. Hitachi Ltd and Nachi-Fujikoshi were also found guilty of price-fixing but the authorities exempted these firms from monetary penalties for their cooperation in the investigation.
The penalties prompted many to accuse NDRC of targeting foreign firms, but NDRC Secretary General Li Pumin refuted the accusation, saying everyone was equal before China's law.
Refuting the accusation, Pumin said, "Everyone is equal before the law. No matter whether they are domestic or foreign-funded firms, they will be punished if they violate the law."
The combined fine of $200 million on auto parts manufacturers is the biggest antitrust fine doled out by China since relevant rules took effect nearly six years ago.
There are a lot of things not going right at the IRS and mostly so when it comes to filing for Earned Income Tax Credits (EITC).
In December 2014, a report by Watchdog.org showed that that an audit by the IRS documented twenty four percent...
A new study by the Massachusetts Institute of Technology (MIT) has revealed that Istanbul lies...
The Michael J Fox Foundation is aiming to test wearable sensors in smart watches made by Intel's...
There was a time just a few years back when Spain ranked second after Greece, as a figure of the euro zone's huge debt crisis and economic slowdown. The country's unemployment climbed to a huge twenty seven percent and the economy was still...
In January, trade surplus of Germany decreased since plunge in imports was more than a drop in...
On Tuesday, tech giant Google released latest to show how much of its online traffic is...
German drugmaker Merck said that its experimental cancer medicine evofosfamidehas failed in the last stage of clinical tests due to which it won't seek regulatory approval for its treatment.
On Monday, Darmstadt, Germany-based Merck said...
On Thursday, the US Federal Bureau of Investigation (FBI...
In an announcement made via a blog post on Thursday,...
In a blog post published on Wednesday, Twitter-owned...
A draft New York legislation proposes the use of a...
© 2011 AustrianTribune - Tribune Online Services. All times CET (GMT + 1.00).